Volume 6.26 | Jul 7

Hematopoiesis News 6.26 July 7, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   HN on Twitter
Largest Study of Gene Mutations in Aplastic Anemia May Help Optimize Treatment
Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement. [Press release from the National Heart, Lung, and Blood Institute discussing online publication in the New England Journal of Medicine] Press Release | Abstract
Learn more about our standardized tools for cord blood banking
PUBLICATIONS (Ranked by impact factor of the journal)
Mutation of kri1l Causes Definitive Hematopoiesis Failure via PERK-Dependent Excessive Autophagy Induction
Through genetic mapping, molecular cloning and mechanism characterization of the zebrafish mutant cas002, investigators revealed a novel connection between ribosomal dysfunction and excessive autophagy in the regulation of hematopoietic stem/progenitor cells. [Cell Res] Full Article

Coordinate Regulation of Residual Bone Marrow Function by Paracrine Trafficking of AML Exosomes
In a series of in vitro studies and murine xenografts, scientists demonstrated that acute myeloid leukemia (AML) exosomes downregulate critical retention factors in stromal cells, leading to hematopoietic stem and progenitor cell mobilization from the bone marrow. [Leukemia] Abstract

TopBP1 Governs Hematopoietic Stem/Progenitor Cells Survival in Zebrafish Definitive Hematopoiesis
Researchers report that a novel zebrafish mutantcas003 with nonsense mutation in topbp1 gene encoding topoisomerase II beta binding protein 1 (TopBP1) exhibits severe definitive hematopoiesis failure. [PLoS Genet] Full Article

Transcription and Methylation Analysis of Preleukemic Promyelocytes Indicate a Dual Role for PML/RARA in Leukemia Initiation
Utilizing a novel sorting strategy, investigators isolated highly purified promyelocyte populations, from normal versus young preleukemic animals, and carried out microarray and methylation profiling analyses. In the absence of secondary lesions, PML/RARA had an overall limited impact on both the transcriptome and methylome. [Haematologica] Abstract | Full Article

Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout Mice
Scientists employed a reversible murine model of telomerase deficiency to compare the dependence of erythroid and myeloid lineage differentiation on telomerase activity. [PLoS One] Full Article

Recruitment of CD8+ T Cells into Bone Marrow Might Explain the Suppression of Megakaryocyte Apoptosis through High Expression of CX3CR1+ in Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation
Investigators analyzed the expression of CX3CR1 on CD4 and CD8 T cells in bone marrow and peripheral blood at +90 days from allogeneic hematopoietic stem cell transplantation recipients with or without prolonged isolated thrombocytopenia by flow cytometry analyses. [Ann Hematol] Abstract

Recurrent Abnormal Clones in Myelodysplastic Syndrome Marrow Originate from Cells at a Pluripotent Stem Level and Maintain Their Early Differentiation Potency
Scientists investigated the origins and differentiation potencies of four common malignant clonal cell types in myelodysplastic syndrome and to investigate whether the trisomy of chromosome 8 occurs subsequently to other chromosomal abnormalities. [Cancer Invest] Abstract


Long-Term Outcome of a Phase II Trial with Nilotinib 400 mg Twice Daily in First-Line Treatment of Chronic Myeloid Leukemia
Researchers report the long-term, six-year, results of the first investigator-sponsored, GIMEMA multicenter Phase II, single-arm, trial with nilotinib 400 mg twice daily as first-line treatment in 73 chronic-phase chronic myeloid leukemia patients. [Haematologica] Abstract | Full Article

Comparable Outcome after Single-Antigen-Mismatched versus Matched Unrelated Donor Hematopoietic Cell Transplantation
The impact of donor matching on outcome of unrelated hematopoietic stem cell transplantation was analyzed in patients transplanted at the University of Leipzig. [J Cancer Res Clin Oncol] Abstract

Standardize Your CFU Assays With STEMvision for Automated CFU Assay Imaging and Analysis
Deconstructing Innate Immune Signaling in Myelodysplastic Syndromes
The authors discuss the contribution of chronic toll-like receptor signaling to the pathogenesis of myelodysplastic syndromes based on evidence from patients and mouse genetic models. [Exp Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
AMAG Pharmaceuticals to Acquire Cord Blood Registry
AMAG Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to acquire Cord Blood Registry®, the world’s largest stem cell collection and storage company serving pregnant women and their families, for $700 million. [Cord Blood Registry®] Press Release

Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
Genmab A/S announced that a variation to the Marketing Authorization has been submitted to the European Medicines Agency for the use of ofatumumab as maintenance therapy of patients with relapsed chronic lymphocytic leukemia (CLL). [Genmab A/S] Press Release

Amarna Therapeutics Teaming Up with Austrian CBmed in the Development of Immunotherapies
Amarna Therapeutics announced that it has entered into a cooperation with Austrian Center for Biomarker Research in Medicine (CBmed), for the development of immunotherapies against acute lymphoblastic leukemia, obesity, diabetes mellitus type 2 and atherosclerotic cardiovascular disease. [Amarna Therapeutics B.V.] Press Release

From our sponsor: Working with blood? Download the immune cell frequencies app.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd International Annual Conference of the German Stem Cell Network (GSCN)
September 9-11, 2015
Frankfurt, Germany

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Position – Splicing in Hematopoiesis (Northwestern University)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Clinical Research Coordinator – Chronic Lymphocytic Leukemia (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Transplantation (St. Jude Children’s Research Hospital)

Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Postdoctoral Fellow – Immune Tolerance (Stanford University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institute)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us